Is Bausch Health Companies Inc. (BHC) a good stock to buy?

Olyth's institutional analysis of BHC reveals an Altman Z-Score of 0.23 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($10.31B most recent), help investors decide if BHC fits their risk profile.

What is the current P/E ratio for BHC?

As of the latest trading session, Bausch Health Companies Inc. (BHC) has a trailing P/E ratio of 12.67.

Who is the CEO of Bausch Health Companies Inc.?

The current Chief Executive Officer of Bausch Health Companies Inc. is Thomas J. Appio.

What was BHC's revenue for the last 5 years?

According to its latest income statements, Bausch Health Companies Inc. reported annual revenues of $10.31B (2025), $9.63B (2024), $8.76B (2023), $8.12B (2022), $8.43B (2021) respectively.

Does BHC pay a dividend?

Bausch Health Companies Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does BHC have?

In its latest reporting period, Bausch Health Companies Inc. generated $1.00B in Free Cash Flow against a total debt load of $21.21B.

What is the Price-to-Book (P/B) ratio of Bausch Health Companies Inc.?

The Price-to-Book (P/B) ratio for Bausch Health Companies Inc. (BHC) is currently -3.56.

What is the Price-to-Sales (P/S) ratio of BHC?

Based on trailing twelve-month data, Bausch Health Companies Inc. (BHC) trades at a Price-to-Sales (P/S) ratio of 0.19.

What is Bausch Health Companies Inc.'s Return on Equity (ROE)?

Bausch Health Companies Inc. (BHC) has a Return on Equity (ROE) of -20.27%, representing its profitability relative to shareholder equity.

BHC

Bausch Health Companies Inc. · Healthcare

5.31

1.85%(-0.10)

Market Open

Last Updated: — ET

52W L: $4.2552W H: $8.69

$5.26

CHG-0.13 (-2.41%)

H$5.62

L$4.78

VOL30M

BHC (1h)

Company Profile

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

20,700

IPO Date

1994-03-29

Beta

0.40

Websitewww.bauschhealth.com↗

BHC

Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

Is the Options Market Predicting a Spike in Bausch Health Stock?

Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm